VBLT Vascular Biogenics Ltd.

1.32
-0.14  -10%
Previous Close 1.46
Open 1.49
Price To Book 1.33
Market Cap 47,716,334
Shares 36,148,738
Volume 357,912
Short Ratio
Av. Daily Volume 146,276
Stock charts supplied by TradingView

NewsSee all news

  1. VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study

    OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10% or higher in CA-125

  2. VBL Therapeutics Announces Year Ended December 31, 2019 Financial Results and Provides Corporate Update

    The OVAL Phase 3 potential-registration study of VB-111 in ovarian cancer continues as planned towards the important interim analysis in 1Q 2020VB-111 clinical program expands to include U.S. NCI-sponsored study in colon

  3. VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19

    TEL AVIV, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for

  4. VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer

    This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor.Pathology readouts are expected to shed light on the potential of VB-111 to turn "cold" colorectal tumors "hot."

  5. VBL Therapeutics to Present at the BIO CEO & Investor Conference

    TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim analysis noted that the DSMC recommended that the study proceed without modification. Overall CA-125 response rate in the first 60 randomized evaluable patients was 53%.
VB-111
Recurrent platinum resistant ovarian cancer
Phase 3 top-line data released March 8, 2018 - primary endpoint not met.
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Psoriasis
Phase 2 trial to be initiated 4Q 2019.
VB-111
Colon cancer
Phase 2 trial to be initiated 4Q 2019.
VB-111
Recurrent glioblastoma multiforme (rGBM)
Phase 2 initiation announced February 20, 2020.
VB-111 and Nivolumab
Colorectal Cancer

Latest News

  1. VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study

    OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10% or higher in CA-125

  2. VBL Therapeutics Announces Year Ended December 31, 2019 Financial Results and Provides Corporate Update

    The OVAL Phase 3 potential-registration study of VB-111 in ovarian cancer continues as planned towards the important interim analysis in 1Q 2020VB-111 clinical program expands to include U.S. NCI-sponsored study in colon

  3. VBL Therapeutics to Report Fourth Quarter 2019 Financial Results on March 19

    TEL AVIV, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for

  4. VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer

    This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor.Pathology readouts are expected to shed light on the potential of VB-111 to turn "cold" colorectal tumors "hot."

  5. VBL Therapeutics to Present at the BIO CEO & Investor Conference

    TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for

  6. VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study

    TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent

  7. VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented

  8. VBL Therapeutics Announces Third Quarter 2019 Financial Results

    TEL AVIV, Israel, Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced financial results for the third quarter ended September 30, 2019, and provided a corporate update. "Our OVAL Phase 3

  9. VBL Therapeutics Announces New IND for an Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma

    Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel, Nov. 06, 2019 (GLOBE

  10. VBL Therapeutics to Report Third Quarter 2019 Financial Results on November 14

    TEL AVIV, Israel, Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for